Who
George Poste
Director
Company insider
Files Form 4 as: Director, Caris Life Sciences; Director, Exelixis; Director, Monsanto Co /new/; Director, Orchid Cellmark.
In numbers
- Trades disclosed
- 168
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $17.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 27 Jan 2006
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | $25K1,600 at $15.62 | filing |
| 29 May 2026filed 2 Jun 2026 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code A | $25K1,600 at $15.62 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.7M60,000 at $45.71 | filing |
| 7 May 2026filed 8 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.7M60,000 at $45.71 | filing |
| 11 Aug 2025filed 13 Aug 2025 | CAI Caris Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —125,000 at $0.00 | filing |
| 11 Aug 2025filed 13 Aug 2025 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code M | $305K125,000 at $2.44 | filing |
| 11 Aug 2025filed 13 Aug 2025 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $1.4M48,022 at $29.75 | filing |
| 11 Aug 2025filed 13 Aug 2025 | CAI Caris Life SciencesDiagnostics & Labs | SEC FORM 4 Code F | $2.7M91,495 at $29.75 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 16 May 2025filed 16 May 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,634 at $0.00 | filing |
| 16 May 2025filed 16 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $408K20,634 at $19.77 | filing |
| 16 May 2025filed 16 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $949K20,634 at $45.99 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL Exelixisoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,874 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code M | $325K15,874 at $20.50 | filing |
| 14 Feb 2025filed 19 Feb 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $551K15,874 at $34.74 | filing |
| 1 Nov 2024filed 5 Nov 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.0M30,000 at $34.00 | filing |
| 8 Aug 2024filed 12 Aug 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $907K33,725 at $26.89 | filing |
| 31 May 2024filed 4 Jun 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —18,838 at $0.00 | filing |
News
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026Exelixis v. MSN Shows the Reach of Earlier Genus PatentsEXEL · natlawreview.com · 7 Oct 2026
0 headlines in the last 90 days name George Poste; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.